Literature DB >> 25908731

Endovascular intervention for peripheral artery disease.

Arun K Thukkani1, Scott Kinlay2.   

Abstract

Advances in endovascular therapies during the past decade have broadened the options for treating peripheral vascular disease percutaneously. Endovascular treatment offers a lower risk alternative to open surgery in many patients with multiple comorbidities. Noninvasive physiological tests and arterial imaging precede an endovascular intervention and help localize the disease and plan the procedure. The timing and need for revascularization are broadly related to the 3 main clinical presentations of claudication, critical limb ischemia, and acute limb ischemia. Many patients with claudication can be treated by exercise and medical therapy. Endovascular procedures are considered when these fail to improve quality of life and function. In contrast, critical limb ischemia and acute limb ischemia threaten the limb and require more urgent revascularization. In general, endovascular treatments have greater long-term durability for aortoiliac disease than femoral popliteal disease. Infrapopliteal revascularization is generally reserved for critical and acute limb ischemia. Balloon angioplasty and stenting are the mainstays of endovascular therapy. New well-tested innovations include drug-eluting stents and drug-coated balloons. Adjunctive devices for crossing chronic total occlusions or debulking plaque with atherectomy are less rigorously studied and have niche roles. Patients receiving endovascular procedures need a structured surveillance plan for follow-up care. This includes intensive treatment of cardiovascular risk factors to prevent myocardial infarction and stroke, which are the main causes of death. Limb surveillance aims to identify restenosis and new disease beyond the intervened segments, both of which may jeopardize patency and lead to recurrent symptoms, functional impairment, or a threatened limb.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  endovascular procedures; intermittent claudication; peripheral artery disease

Mesh:

Year:  2015        PMID: 25908731      PMCID: PMC4504240          DOI: 10.1161/CIRCRESAHA.116.303503

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  131 in total

1.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

2.  Primary iliac stenting versus transluminal angioplasty with selective stenting.

Authors:  Ali F AbuRahma; J David Hayes; Sarah K Flaherty; William Peery
Journal:  J Vasc Surg       Date:  2007-10-01       Impact factor: 4.268

3.  Pooled analysis of the CONFIRM registries: safety outcomes in diabetic patients treated with orbital atherectomy for peripheral artery disease.

Authors:  Michael S Lee; Tae Yang; George Adams
Journal:  J Endovasc Ther       Date:  2014-04       Impact factor: 3.487

4.  Drug-coated balloons for infrapopliteal disease: digging deep to understand the impact of a negative trial.

Authors:  John R Laird; Ehrin J Armstrong
Journal:  J Am Coll Cardiol       Date:  2014-10-14       Impact factor: 24.094

5.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.

Authors:  M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin
Journal:  JAMA       Date:  2001-10-03       Impact factor: 56.272

6.  Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity.

Authors:  F A Weaver; A J Comerota; M Youngblood; J Froehlich; J D Hosking; G Papanicolaou
Journal:  J Vasc Surg       Date:  1996-10       Impact factor: 4.268

7.  A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia.

Authors:  Jonathan L Eliason; Reid M Wainess; Mary C Proctor; Justin B Dimick; John A Cowan; Gilbert R Upchurch; James C Stanley; Peter K Henke
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

8.  Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group.

Authors:  E Tetteroo; Y van der Graaf; J L Bosch; A D van Engelen; M G Hunink; B C Eikelboom; W P Mali
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

9.  Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial.

Authors:  Richard R Saxon; Arun Chervu; Paul A Jones; Tanvir K Bajwa; Dennis R Gable; Peter A Soukas; Richard J Begg; John G Adams; Gary M Ansel; Darren B Schneider; Charles M Eichler; Michael J Rush
Journal:  J Vasc Interv Radiol       Date:  2013-01-28       Impact factor: 3.464

10.  Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial.

Authors:  Thomas Zeller; Iris Baumgartner; Dierk Scheinert; Marianne Brodmann; Marc Bosiers; Antonio Micari; Patrick Peeters; Frank Vermassen; Mario Landini; David B Snead; K Craig Kent; Krishna J Rocha-Singh
Journal:  J Am Coll Cardiol       Date:  2014-10-14       Impact factor: 24.094

View more
  40 in total

1.  Effects of Intravenous and Catheter Directed Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator (Alteplase) in Non-Traumatic Acute Limb Ischemia; A Randomized Double-Blind Clinical Trial.

Authors:  Abbas Saroukhani; Hassan Ravari; Masoud Pezeshki Rad
Journal:  Bull Emerg Trauma       Date:  2015-07

2.  Update on peripheral artery disease: Epidemiology and evidence-based facts.

Authors:  Jun Shu; Gaetano Santulli
Journal:  Atherosclerosis       Date:  2018-05-22       Impact factor: 5.162

3.  Lower extremity computed tomography angiography can help predict technical success of endovascular revascularization in the superficial femoral and popliteal artery.

Authors:  Nathan K Itoga; Tanner Kim; Anna M Sailer; Dominik Fleischmann; Matthew W Mell
Journal:  J Vasc Surg       Date:  2017-05-11       Impact factor: 4.268

4.  Methods for Acute and Subacute Murine Hindlimb Ischemia.

Authors:  Michael E Padgett; Timothy J McCord; Joseph M McClung; Christopher D Kontos
Journal:  J Vis Exp       Date:  2016-06-21       Impact factor: 1.355

5.  Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.

Authors:  Rohun U Palekar; Chandu Vemuri; Jon N Marsh; Batool Arif; Samuel A Wickline
Journal:  J Vasc Surg       Date:  2015-10-17       Impact factor: 4.268

6.  Management of Critical Limb Ischemia.

Authors:  Scott Kinlay
Journal:  Circ Cardiovasc Interv       Date:  2016-02       Impact factor: 6.546

7.  Evaluation of a novel 2D perfusion angiography technique independent of pump injections for assessment of interventional treatment of peripheral vascular disease.

Authors:  Jan B Hinrichs; Tim Murray; Muharrem Akin; Michael Lee; Micheal Ulrich Brehm; Mathias Wilhelmi; Frank K Wacker; Thomas Rodt
Journal:  Int J Cardiovasc Imaging       Date:  2016-10-26       Impact factor: 2.357

Review 8.  Rock-Hard Chronic Thrombotic Occlusion and Its Management in Endovascular Interventions.

Authors:  Sreekumar Madassery
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

9.  Techniques in Vascular and Interventional Radiology Drug Delivery Technologies in the Superficial Femoral Artery.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Tech Vasc Interv Radiol       Date:  2016-05-05

Review 10.  Antithrombotic Therapy After Peripheral Vascular Intervention.

Authors:  Peter Hu; Schuyler Jones
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.